Corvus Pharmaceuticals, Inc.
NASDAQ:CRVSBiotechnology
-$0.19 today
- Market cap
- $859.56M
- Beta
- 0.84
- P/E (TTM)
- -24.1
- EPS (TTM)
- -$0.49
Volume 0.99M
Average 1.49M
CRVS Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Corvus Pharmaceuticals, Inc.NASDAQ: CRVS
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $2.65M rose 111.8% year over year, ahead of the +88.8% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 68.4% from the prior quarter. Over 3 fiscal years it compounded at +25.6% a year.
Context
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +111.8% holds above the trailing-twelve-month pace of +88.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 5.33M USD
- Year-over-year change
- +77.5%
- 4-year CAGR
- +5.9%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.33M | +77.5% |
| FY2024 | 2024-12-31 | 3M | +39.9% |
| FY2023 | 2023-12-31 | 2.15M | -20.2% |
| FY2022 | 2022-12-31 | 2.69M | -36.4% |
| FY2021 | 2021-12-31 | 4.23M | — |
Stock-Based Compensation vs competitors
How CRVS compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +88.8% is the highest of 8, against a peer median of -6.0%.
- Over three fiscal years its annual growth of +25.6% compares with a peer median of -16.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $63M USD | -6.0% | -2.6% | 53.8% | |
| LTM Mar 2026 | $21.99M USD | -15.0% | -30.6% | 46.9% | |
| LTM Mar 2026 | $12.55M USD | -55.6% | -11.3% | 8.0% | |
| LTM Jun 2026 | $11.99M USD | -31.8% | -39.6% | 22.0% | |
| LTM Mar 2026 | $10.93M USD | +20.5% | +16.2% | — | |
| LTM Mar 2026 | $9.12M USD | +17.3% | -21.7% | 25.6% | |
| LTM Jun 2024 | $7.27M USD | — | -29.1% | 891.4% | |
| LTM Mar 2026 | $6.73M USD | +88.8% | +25.6% | — | |
| FY2025 | €4.26M EUR | +7.9% | +0.1% | 152.7% | |
| LTM Dec 2025 | $0 USD | — | — | 0.0% | |
| Peer median (excluding CRVS) | — | -6.0% | -16.5% | 36.3% | |
Competitors are the stored peer set for CRVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (43.24M) | (41.31M) | (27.03M) | (62.29M) | (15.28M) |
| Depreciation & Amortization | 460K | 367K | 151K | 85K | 105K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.23M | 2.69M | 2.15M | 3M | 5.33M |
| Change in Working Capital | (3.24M) | 1.41M | (3.59M) | (1.65M) | 3.58M |
| Accounts Receivables | (507K) | (81K) | 562K | (49K) | 38K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.9M) | 411K | (451K) | 1.06M | (91K) |
| Other Working Capital | (827K) | 1.08M | (3.71M) | (2.66M) | 3.63M |
| Other Non-Cash Items | 5.07M | 9.81M | 4.39M | 35.43M | (26.53M) |
| Operating Cash Flow | (36.72M) | (27.02M) | (23.94M) | (25.42M) | (32.8M) |
| Capital Expenditures | (5K) | (269K) | (34K) | 0 | (174K) |
| Acquisitions (Net) | (21.57K) | 22K | 0 | 5K | 0 |
| Purchases of Investments | (9.36M) | (66.19M) | (47.05M) | (70.12M) | (91.75M) |
| Sales of Investments | 30.92M | 43.16M | 62.62M | 42.63M | 84.13M |
| Other Investing Activities | 21.57K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 21.56M | (23.28M) | 15.54M | (27.48M) | (7.8M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 60.94M | 0 | 7.84M | 16.41M | 36.43M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.22M | 0 | 12K | 32.62M | 0 |
| Financing Cash Flow | 62.16M | 0 | 7.86M | 49.03M | 36.43M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 47M | (50.3M) | (539K) | (3.88M) | (4.16M) |
| Free Cash Flow | (36.72M) | (27.29M) | (23.97M) | (25.42M) | (32.97M) |
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
Intrinsic Alpha fair value
Locked
Current Price
$10.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.